ARRY - Array BioPharma Inc.
| Previous Close | 29.42 |
| Open | 29.54 |
| Bid | 29.40 x 800 |
| Ask | 29.57 x 4000 |
| Day's Range | 29.06 - 29.74 |
| 52 Week Range | 12.56 - 29.81 |
| Volume | 1,672,717 |
| Avg. Volume | 2,815,971 |
| Market Cap | 6.562B |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire•12 days ago
Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference
BOULDER, Colo. , June 4, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Operating Officer, Andrew Robbins , will speak at the Goldman Sachs 40th Annual Global Healthcare ...
- PR Newswire•18 days ago
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
BOULDER, Colo. , May 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Jefferies 2019 Global Healthcare Conference ...
- PR Newswire•18 days ago
Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months - - Landmark analysis estimates 47% and 39% of patients ...
- PR Newswire•26 days ago
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be ...
- PR Newswire•last month
Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
BOULDER, Colo. , May 9, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Bank of America Merrill Lynch 2019 Health ...
- PR Newswire•last month
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter - - BEACON CRC Phase 3 trial interim analysis remains on track to report out this ...
- PR Newswire•2 months ago
Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019
BOULDER, Colo. , April 30, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results ...
- PR Newswire•3 months ago
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer
BOULDER, Colo. , March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network ® (NCCN ® ) has updated their Clinical Practice Guidelines ...
- PR Newswire•3 months ago
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
BOULDER, Colo. , March 5, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference ...
- GlobeNewswire•3 months ago
Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- PR Newswire•4 months ago
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
BOULDER, Colo. , Feb. 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the SVB Leerink Partners 8 th Annual Global ...
- PR Newswire•4 months ago
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% - - Combination of BRAFTOVI, MEKTOVI ...
- PR Newswire•5 months ago
Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019
BOULDER, Colo. , Jan. 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results ...
- ACCESSWIRE•5 months ago
Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
- PR Newswire•5 months ago
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
- Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium - - Updated confirmed ORR remains 48% and updated median PFS remains 8.0 months - - Investor webcast will be held on Tuesday, January ...
- PR Newswire•6 months ago
Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
BOULDER, Colo. , Dec. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 37 th Annual J.P. Morgan Healthcare ...
- ACCESSWIRE•6 months ago
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
- PR Newswire•7 months ago
Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
BOULDER, Colo. , Nov. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 30 th Annual Piper Jaffray Healthcare ...
- PR Newswire•7 months ago
Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference
BOULDER, Colo. , Nov. 6, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Stifel 2018 Healthcare Conference and ...
- GlobeNewswire•7 months ago
Analysis: Positioning to Benefit within Array BioPharma, SPX FLOW, Holly Energy Partners, Electro Scientific Industries, Leggett & Platt, and CBL & Associates Properties — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•8 months ago
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
- Strong launch quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $14 million in net sales - - European Commission approves BRAFTOVI + MEKTOVI for advanced BRAF-mutant melanoma ...
- ACCESSWIRE•8 months ago
Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Array BioPharma
NEW YORK, NY / ACCESSWIRE / October 26, 2018 / U.S. equities bounced back on Thursday supported mostly by gains in consumer discretionary and technology shares. The Dow Jones Industrial Average jumped ...
- PR Newswire•8 months ago
Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018
BOULDER, Colo. , Oct. 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results ...
- PR Newswire•9 months ago
Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference
BOULDER, Colo. , Sept. 25, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 2018 Cantor Global Healthcare Conference ...